Sign up to save your podcasts
Or
Share What’s Material in ESG for Biopharma Firms?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
What’s Material in ESG for Biopharma Firms?
For biopharma companies, ESG commitments can look considerably different from other sectors. We spoke with the team of ESG leads at Gilead Sciences to understand the five key components driving its ESG strategy, how it’s evolved and how it impacts their business.
View all episodes
By RBC Capital Markets
5
1212 ratings
For biopharma companies, ESG commitments can look considerably different from other sectors. We spoke with the team of ESG leads at Gilead Sciences to understand the five key components driving its ESG strategy, how it’s evolved and how it impacts their business.
More shows like Pathfinders in Biopharma
View all
Motley Fool Money
3,221 Listeners
WSJ Your Money Briefing
1,721 Listeners
Exchanges
973 Listeners
Odd Lots
1,896 Listeners
WSJ Tech News Briefing
1,639 Listeners
a16z Podcast
1,100 Listeners
The Long Run with Luke Timmerman
123 Listeners
The Readout Loud
324 Listeners
Wall Street Breakfast
1,040 Listeners
Thoughts on the Market
1,304 Listeners
The Journal.
6,072 Listeners
BioCentury This Week
34 Listeners
RBC's Markets in Motion
40 Listeners
Biotech Hangout
19 Listeners
Industries in Motion
10 Listeners
Powering Sustainable Ideas
0 Listeners
The Markets
74 Listeners
Strategic Alternatives
18 Listeners
The Top Line
14 Listeners
Macro Minutes
3 Listeners